Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

31.3K
Overview
31.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global health inequities in thyroid cancer among adolescents and young adults from overdiagnosis to inadequate care by the socio-demographic index.

Global health research and policy·2026
Same author

Predicting T790M mutation status in non-small cell lung cancer based on radiomics: A systematic review and meta-analysis.

PloS one·2026
Same author

Disruption of the S1/S2 multibasic cleavage site attenuates infectious bronchitis virus, while S2' partially restores viral virulence and expands tissue tropism.

Journal of virology·2026
Same author

Numerical Study of Human Torso Mechanical Response and Injury Assessment Under Blast Loading with Bulletproof Protection.

Annals of biomedical engineering·2026
Same author

New insights into progenitor exhausted T cell populations.

Nature reviews. Immunology·2026
Same author

Imipramine inhibits feline infectious peritonitis virus infection by targeting host cholesterol metabolism via NPC1.

Antimicrobial agents and chemotherapy·2026

Related Experiment Video

Updated: Jul 20, 2025

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

3.1K

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.

Mengqi Yuan1, Yanzhi Zhu2, Guanlan Liu1

  • 1Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, 100193 China.

One Health Advances
|July 31, 2023
PubMed
Summary

A novel bispecific antibody, Bi-Nab, effectively neutralizes SARS-CoV-2 variants, including Omicron. This antibody offers a promising therapeutic strategy against evolving COVID-19 strains by targeting conserved regions of the virus.

Keywords:
Bispecific antibodiesEscape variantsNeutralizing antibodiesOmicron variantsSARS-CoV-2

More Related Videos

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.9K
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
07:08

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

5.1K

Related Experiment Videos

Last Updated: Jul 20, 2025

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

3.1K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.9K
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
07:08

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

5.1K

Area of Science:

  • Immunology and Virology
  • Therapeutic Antibody Development

Background:

  • Monospecific neutralizing antibodies (nAbs) face challenges from emerging SARS-CoV-2 variants.
  • Neutralizing antibody escape variants necessitate the development of broader therapeutic strategies.

Purpose of the Study:

  • To develop and evaluate an IgG-like bispecific antibody (bsAb), Bi-Nab, targeting conserved sites on the SARS-CoV-2 spike receptor binding domain (RBD).
  • To assess Bi-Nab's binding affinity, neutralization potency, and breadth against SARS-CoV-2 variants, including Omicron.

Main Methods:

  • Generation of an IgG-like bispecific antibody (Bi-Nab) using human nAbs 35B5 and 32C7.
  • Assessment of binding affinity to the Delta spike protein.
  • Evaluation of inhibition of RBD-ACE2 binding.
  • Pseudovirus neutralization assays against wild-type, VBMs, VOCs, and Omicron variants.

Main Results:

  • Bi-Nab demonstrated higher binding affinity to the Delta spike protein compared to parental antibodies.
  • Bi-Nab effectively inhibited RBD-ACE2 binding and showed improved neutralization potency and breadth against various SARS-CoV-2 variants.
  • Bi-Nab exhibited enhanced neutralization against Omicron variants, surpassing parental monoclonal antibody and cocktail efficacy, indicating synergistic neutralization.

Conclusions:

  • The bispecific antibody Bi-Nab is a feasible and effective therapeutic strategy against SARS-CoV-2.
  • Bi-Nab demonstrates potent neutralizing activity and broad coverage against current and emerging SARS-CoV-2 variants of concern.